Publications by authors named "Matteo Prinetti"
Strike early-strike strong lipid-lowering strategy with proprotein convertase subtilisin/kexin type 9 inhibitors in acute coronary syndrome patients: real-world evidence from the AT-TARGET-IT registry.
Paola Gargiulo
,
Christian Basile
,
Gennaro Galasso
,
Michele Bellino
,
Debora D'Elia
,
Matteo Prinetti
Eur J Prev Cardiol
November 2024
Article Synopsis
- This study examines the impact of starting PCSK9 inhibitors (PCSK9i) at the time of hospitalization for acute coronary syndrome (ACS) on lipid levels and cardiovascular (CV) events in a real-world setting.
- It analyzed data from 771 ACS patients, revealing that a significant 68.3% achieved the target LDL-C of < 55 mg/dL within a median of 37 days after hospitalization.
- Results showed that lower LDL-C levels were associated with reduced risks of major cardiovascular events, suggesting that early and aggressive lipid management with PCSK9i is both safe and beneficial for ACS patients.